Oxford Cannabinoid Technologies (OCTP) Share Price, News & Analysis

Company Overview

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. In addition, its development pipeline includes cannabinoid derivative products comprising OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indications; and immunotherapy agents for the treatment of solid tumours. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 0.12 to 0.12
• 52-Week Range: N/A
• Volume: 11.40 million shs
• Average Volume: 9.33 million shs
• Market Capitalization: £1.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OCTP Stock Analysis - Frequently Asked Questions

How do I buy shares of Oxford Cannabinoid Technologies?

Shares of OCTP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Oxford Cannabinoid Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Cannabinoid Technologies investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Brookfield Business Partners (BBU.UN), Bearing Lithium (BRZ), (BSFT) (BSFT), BTCS (BTCS) and BTC Digital (BTCTW).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:OCTP
• CUSIP: N/A
• CIK: N/A
• Web: www.oxcantech.com
• Phone: 44 20 3034 2820
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-4,240,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -86.76%
• Return on Assets: -53.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.32
• Quick Ratio: 5.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,090,000,000
• Free Float: N/A
• Market Cap: £1.25 million
• Optionable: Not Optionable
• Beta: 0.82